Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 6,000 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. bought 6,000 shares of Anixa Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was purchased at an average cost of $2.59 per share, with a total value of $15,540.00. Following the completion of the acquisition, the director now directly owns 928,334 shares in the company, valued at $2,404,385.06. This represents a 0.65 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anixa Biosciences Price Performance

ANIX stock opened at $2.82 on Friday. The company has a market capitalization of $90.80 million, a price-to-earnings ratio of -7.23 and a beta of 0.90. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $4.79. The business has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $3.04.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Sell-side analysts anticipate that Anixa Biosciences, Inc. will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

Several large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in Anixa Biosciences during the 3rd quarter valued at approximately $34,000. Westside Investment Management Inc. grew its holdings in shares of Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. International Assets Investment Management LLC increased its position in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Finally, Tyler Stone Wealth Management raised its stake in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares in the last quarter. 29.13% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ANIX shares. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.